Related Experiment Video
Updated: May 4, 2026

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Cerebral vein thrombosis in a four year old with Behçet's disease
Duygu Ovunc Hacihamdioglu1, Murat Demiriz2, Gungor Sobaci3
1Gulhane Military Medical Academy, Medicine School, Department of Pediatrics, Division of Pediatric Nephrology and Rheumatology, Turkey.
Insights
This study presents the youngest case of Behçet's disease (BD) with sagittal sinus thrombosis in a four-year-old child. Infliximab therapy showed promise for treating this rare pediatric neurological complication.
Area of Science:
- Vascular Medicine
- Pediatric Neurology
- Rheumatology
Background:
- Behçet's disease (BD) is a multisystemic inflammatory disorder characterized by vasculitis affecting various blood vessels.
- Central nervous system (CNS) involvement occurs in 5-10% of BD patients, with neurological symptoms typically appearing after 3-6 years of disease onset.
- Pediatric BD, though rare, can lead to increased morbidity and mortality, with a mean age of onset around 7 years.
Observation:
- A four-year-old Turkish boy, the youngest reported case, presented with Behçet's disease and sagittal sinus thrombosis.
- The patient exhibited papilledema but no overt neurological signs at presentation.
- This case highlights an unusual early presentation of neurological involvement in pediatric BD.
Findings:
- Treatment with infliximab was initiated for the sagittal sinus thrombosis in this pediatric BD patient.
- Initial response to infliximab suggests potential efficacy in managing this severe complication.
- The patient's presentation represents the earliest documented instance of sagittal sinus thrombosis in childhood Behçet's disease.
Implications:
- Infliximab may represent a viable therapeutic option for refractory sagittal sinus thrombosis in pediatric Behçet's disease.
- This case expands the understanding of the clinical spectrum and early manifestations of CNS involvement in childhood BD.
- Further long-term studies are warranted to confirm the sustained efficacy and safety of infliximab in this population.
Abstract:
Behçet's disease (BD) is a multisystem disorder. The main pathology in BD is vasculitis that involves arteries and veins of all calibers. Central nervous system involvement occurs in 5-10% of patients. Increased morbidity and mortality is rarely observed in children. The mean age at onset in pediatric BD is approximately 7 years. Neurologic involvement in BD is usually observed after 3-6 years. We report the case of a four-year-old Turkish boy with BD with sagittal sinus thrombosis treated with infliximab. The patient presented papilledema without neurologic signs. Although long-term efficacy evaluations are needed in this case, infliximab therapy may be a good option in childhood BD with refractory sinus thrombosis. This is the youngest case of BD with sagittal sinus thrombosis reported so far.
Related Concept Videos
Cerebral Edema ll: Pathophysiology
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

